viscum album + pembrolizumab

This is a combination therapy involving the plant extract Viscum album (European mistletoe) and the monoclonal antibody pembrolizumab. Viscum album extracts are used in integrative cancer care to support immune function, reduce side effects, improve quality of life, and possibly slow disease progression or improve survival[6][8]. Pembrolizumab is an immune checkpoint inhibitor targeting PD-1 (programmed cell death protein 1), which blocks the interaction between PD-1 and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune responses[5]. The combination has been studied for safety and efficacy in patients with advanced or metastatic cancer, with evidence suggesting that concomitant use does not significantly alter adverse event rates compared to pembrolizumab alone[1][5].

Other names

Viscum album L. + pembrolizumabmistletoe extract + pembrolizumab